rofecoxib has been researched along with Adverse Drug Event in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It can be postulated that in addition to the risk of heart attack and stroke, rofecoxib users were at increased risk of hemorrhage, in addition to other thrombotic and embolic adverse events, which was exacerbated in those taking blood thinners or NSAIDs." | 3.75 | Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. ( Barry, WT; Bottone, FG, 2009) |
| " Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with COX-2 inhibitors in patients with OA were eligible for inclusion." | 2.61 | Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. ( Baird, J; Bruyère, O; Cooper, C; Corp, N; Curtis, E; Dennison, E; Fuggle, N; Honvo, G; Maggi, S; Ntani, G; Parsons, C; Reginster, JY; Shaw, S; Spooner, L, 2019) |
| "Rofecoxib at 18." | 1.39 | [Drug-related claims in the Norwegian system of compensation to patients]. ( Baardseth, M; Flåte, S; Lynghei, E; Slørdal, L; Spigset, O, 2013) |
| "The study was undertaken to evaluate the contribution of a process which uses clinical trial data plus linked de-identified administrative health data to forecast potential risk of adverse events associated with the use of newly released drugs by older Australian patients." | 1.37 | Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process. ( Eckermann, EJ; Pearce, CM; Ridout, SC; Whitstock, MT, 2011) |
| "We propose a practical group sequential method, a conditional sequential sampling procedure, to test if a drug of interest (D) leads to an elevated risk for an adverse event E compared with a comparison drug C." | 1.35 | A conditional sequential sampling procedure for drug safety surveillance. ( Li, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Curtis, E | 1 |
| Fuggle, N | 1 |
| Shaw, S | 1 |
| Spooner, L | 1 |
| Ntani, G | 1 |
| Parsons, C | 1 |
| Corp, N | 1 |
| Honvo, G | 1 |
| Baird, J | 1 |
| Maggi, S | 1 |
| Dennison, E | 1 |
| Bruyère, O | 1 |
| Reginster, JY | 1 |
| Cooper, C | 1 |
| Barozzi, N | 1 |
| Peeters, GM | 1 |
| Tett, SE | 1 |
| Bottone, FG | 1 |
| Barry, WT | 1 |
| Li, L | 1 |
| Whitstock, MT | 1 |
| Pearce, CM | 1 |
| Ridout, SC | 1 |
| Eckermann, EJ | 1 |
| Avorn, J | 1 |
| Baardseth, M | 1 |
| Lynghei, E | 1 |
| Flåte, S | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Healy, B | 1 |
| Lima Rodríguez, EM | 1 |
| Calvo Romero, JM | 1 |
| Greener, M | 1 |
| Frantz, S | 1 |
| Gorelick, KJ | 1 |
| Waller, PC | 1 |
| Evans, SJ | 1 |
| Beard, K | 1 |
| Wadman, M | 2 |
1 review available for rofecoxib and Adverse Drug Event
| Article | Year |
|---|---|
Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Topics: Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Lactones; Oste | 2019 |
17 other studies available for rofecoxib and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications?
Topics: Aged; Australia; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphospho | 2015 |
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Dr | 2009 |
A conditional sequential sampling procedure for drug safety surveillance.
Topics: Aged; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Evaluation; Drug-Related Si | 2009 |
Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.
Topics: Aged; Aged, 80 and over; Comorbidity; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adv | 2011 |
Two centuries of assessing drug risks.
Topics: Databases, Factual; Drug and Narcotic Control; Drug Evaluation; Drug Therapy; Drug-Related Side Effe | 2012 |
[Drug-related claims in the Norwegian system of compensation to patients].
Topics: Compensation and Redress; Cyclooxygenase 2 Inhibitors; Drug Therapy; Drug-Related Side Effects and A | 2013 |
What is a 'safe' drug?
Topics: Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug-Related Side Effects and Adverse Reaction | 2004 |
[Gastro-intestinal toxicity of rofecoxib].
Topics: Aged; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duodenal Ulcer; Fe | 2005 |
Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
Topics: Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2005 |
Drug safety special: chasing shadows.
Topics: Adverse Drug Reaction Reporting Systems; Cyclooxygenase Inhibitors; Databases, Factual; Drug Industr | 2005 |
What ails the FDA?
Topics: Advertising; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug | 2005 |
Drug safety and regulation.
Topics: Cyclooxygenase Inhibitors; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; L | 2005 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
Experts call for active surveillance of drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Adverse R | 2007 |
Moment of reckoning.
Topics: Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Federal Go | 2007 |